Search alternatives:
significantly increased » significant increase (Expand Search)
significant decrease » significant increase (Expand Search)
significant 17 » significant _ (Expand Search), significant co (Expand Search), significant gap (Expand Search)
17 decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significantly increased » significant increase (Expand Search)
significant decrease » significant increase (Expand Search)
significant 17 » significant _ (Expand Search), significant co (Expand Search), significant gap (Expand Search)
17 decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
281
-
282
-
283
-
284
-
285
-
286
Percent viability and cytotoxicity of NHBE cells are significantly altered by PAA exposure.
Published 2025“…Percent viability significantly decreased with PAA concentration and between recovery times compared to controls. …”
-
287
-
288
-
289
Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX
Published 2024“…The average GSRS scores decreased from 30.17 (before) to 19 (after; p < 0.0001), CARS scores decreased from 36.22 to 33.33 (p < 0.0001), SRS scores decreased from 151.17 to 137.5 (p = 0.0002), and the ABC scores decreased 76.39 to 53.17 (p < 0.0001) in the FMT group. …”
-
290
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
291
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
292
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
293
-
294
-
295
-
296
-
297
-
298
-
299
Histogram of the GO functional enrichment of differential miRNA target genes.
Published 2025Subjects: -
300
Changes in SHR body weight, hemodynamics and cardiac function before and after training.
Published 2025Subjects: